Aifm1 Protein — Apoptosis Inducing Factor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | Apoptosis-Inducing Factor, Mitochondria-Associated 1 |
|---|---|
| Gene | [AIFM1](/genes/aifm1) |
| UniProt ID | [O95831](https://www.uniprot.org/uniprot/O95831) |
| Protein Size | 613 amino acids (~63 kDa) |
| Subcellular Localization | Inner mitochondrial membrane (mature form); nucleus (during apoptosis) |
| Protein Family | FAD-dependent oxidoreductases; AIF family |
| PDB Structures | [1GV4](https://www.ebi.ac.uk/pdbe/search/pdb/1GV4), [1M6I](https://www.ebi.ac.uk/pdbe/search/pdb/1M6I), [3PHC](https://www.ebi.ac.uk/pdbe/search/pdb/3PHC) |
Apoptosis-Inducing Factor (AIF) is a crucial flavoprotein that plays dual roles in both normal mitochondrial function and programmed cell death. As a key mediator of caspase-independent apoptosis, AIF translocates from mitochondria to the nucleus upon apoptotic stimuli, where it triggers large-scale DNA fragmentation and chromatin condensation.
The AIF protein contains several distinct structural domains:
The crystal structure reveals a compact globular fold with the FAD-binding domain forming the core of the protein.
In healthy cells, AIF performs essential mitochondrial functions:
Oxidative Phosphorylation: AIF is essential for the assembly and stability of mitochondrial complex I (NADH:ubiquinone oxidoreductase). Loss of AIF leads to severe defects in complex I activity and ATP production[1].
Mitochondrial Morphology: AIF helps maintain normal mitochondrial morphology and cristae structure.
Redox Regulation: The FAD-dependent enzymatic activity allows AIF to participate in cellular redox reactions and antioxidant defense.
DNA Repair: Nuclear AIF can interact with DNA repair proteins to maintain genomic stability.
Recessive mutations in AIFM1 cause X-linked Charcot-Marie-Tooth disease type 4, characterized by peripheral neuropathy, axonal degeneration, and sometimes cognitive impairment[2].
Loss-of-function mutations lead to severe multisystem disorders affecting brain development, causing encephalomyopathy, lactic acidosis, and early-onset neurodegeneration[3].
AIF is sequestered in the cytoplasm in AD brains and translocates to the nucleus in response to amyloid-beta toxicity, contributing to neuronal DNA damage and death[4].
Mitochondrial dysfunction in PD involves impaired AIF function, and PARP-1 activation leads to AIF-mediated cell death (parthanatos)[5].
AIF translocation from mitochondria to nucleus is observed in ALS motor neurons, contributing to progressive neurotoxicity.
Current therapeutic approaches targeting AIF pathway:
AIF interacts with several key proteins:
The study of Aifm1 Protein — Apoptosis Inducing Factor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.